Trial Profile

Phase I Trial of Intraperitoneal 212-Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 212 Pb TCMC trastuzumab (Primary)
Indications Breast cancer; Colon cancer; Endometrial cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions
Sponsors AREVA Med; Orano Med

Most Recent Events

23 Jan 2018 According to an Orano Med media release, AREVA Med changed its name to Orano Med.
29 Sep 2016 Status changed from active, no longer recruiting to completed.
18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov records.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com